Overview

This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicines” – monoclonal antibodies, fusion proteins, and cytokines – that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered. Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies.

Full Product Details

Author:   Giuseppe Tridente
Publisher:   Springer Verlag
Imprint:   Springer Verlag
Edition:   Softcover reprint of the original 1st ed. 2014
Dimensions:   Width: 15.50cm , Height: 3.40cm , Length: 23.50cm
Weight:   9.883kg
ISBN:  

9788847058484

ISBN 10:   8847058481
Pages:   633
Publication Date:   04 May 2017
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Part I General Aspects: 1 Introduction.- 2 Adverse drug events to biomedicines.- 3 Systemic syndromes caused by biomedicines.- Part II Monoclonal antibodies: 4 Monoclonal antibodies.- 5 Abciximab.- 6 Adalimumab.- 7 Alemtuzumab.- 8 Basiliximab.- 9 Belimumab.- 10 Bevacizumab.- 11 Brentuximab.- 12 Canakinumab.- 13 Catumaxomab.- 14.  Certolizumab.- 15 Cetuximab.- 16 Daclizumab.-17 Denosumab.- 18  Eculizumab.- 19 Edrecolomab.- 20 Efalizumab.- 21 Gemtuzumab.- 22 Golimumab.- 23 Ibritumomab.- 24 Infliximab.- 25 Ipilimumab.- 26 Muromonab.- 27 Natalizumab.- 28 Nimotuzumab.- 29 Ofatumumab.- 30 Omalizumab.- 31 Palivizumab.- 32 Panitumumab.- 33 Pertuzumab.- 34Ranibizumab.- 35 Rituximab.- 36 Tocilizumab.- 37 Tositumomab.- 38 Trastuzumab.- 39 Ustekinumab.- Part III Fusion proteins: 40 Fusion proteins.- 41 Abatacept.- 42 Aflibercept.- 43 Alefacept.- 44 Belatacept.- 45 Etanercept.- 46 Rilonacept.- 47 Romiplostim.- Part IV Cytokines : 48 Cytokines.- 49 Interleukins.- 50 Denileukin-diftitox.-51 Anakinra.- 52 Interferons.- 53 Hemopoietic stimulatory factors.- 54 Myelopoietic stimulatory factors.- 55 Thrombopoietic stimulatory factor.- 56 Pluripotent growth factors.- 57 Epidermal growth factors.- Part V Overview: 58 Biomedicines as adverse event inducers.- 59 Conclusions and perspectives.

Reviews

From the reviews: “This is a comprehensive review of existing biological therapeutics and their associated toxicities. … This is a thorough and detailed book, written for experts. … this book is more suitable for researchers in this area and for individuals involved in the regulation or testing of biological drugs. … This is a unique source of detailed information on biological drugs. I would recommend it to anyone interested in this field of research.” (Mitchell R. McGill, Doody’s Book Reviews, March, 2014)

From the reviews: This is a comprehensive review of existing biological therapeutics and their associated toxicities. ... This is a thorough and detailed book, written for experts. ... this book is more suitable for researchers in this area and for individuals involved in the regulation or testing of biological drugs. ... This is a unique source of detailed information on biological drugs. I would recommend it to anyone interested in this field of research. (Mitchell R. McGill, Doody's Book Reviews, March, 2014)

Author Information

Giuseppe Tridente is currently Professor Emeritus of Immunology at the University of Verona, where he was Dean of the Medical Faculty, founder of the Institute of Immunological Sciences, and Director of the Department of Pathology. In 1992 he founded and directed the “Green Channel” Veneto Regional Centre of Surveillance on Adverse Events to Vaccines. His research, mainly devoted to immunopathology, include experimental oncology, tumor immunology, histocompatibility and transplantation, pathophysiology of the thymus, HIV, and adverse events following immunization. He has 146 publications listed on MEDLINE and is also the author of the first Italian textbook on immunology and immunopathology (1979).

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions